Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miltefosine + GM-CSF
- Development stage
- Unknown
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Topical
01
Overview
A combination therapy consisting of oral miltefosine and topically applied granulocyte macrophage colony-stimulating factor (GM-CSF) used for the treatment of cutaneous leishmaniasis, particularly cases caused by Leishmania braziliensis. Miltefosine is an alkylphosphocholine drug with antiparasitic activity, while GM-CSF is an immunomodulator that enhances monocytic function and T-cell responses.
- Other names
- miltefosine + GM-CSFmiltefosine + granulocyte-macrophage colony-stimulating factor
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)
Beyond the preview
Go deeper on miltefosine + GM-CSF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miltefosine + GM-CSF.